SIGNIFICANCE: Melanoma is a deadly cancer that physicians struggle to diagnose early because they lack the knowledge to differentiate benign from malignant lesions. Deep machine learning approaches to image analysis offer promise but lack the transpa...
BACKGROUND: Diagnoses of Skin diseases are frequently delayed in China due to lack of dermatologists. A deep learning-based diagnosis supporting system can facilitate pre-screening patients to prioritize dermatologists' efforts. We aimed to evaluate ...
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Sep 1, 2020
BACKGROUND: Artificial intelligence (AI) is increasingly being used in medical practice. Especially in the image-based diagnosis of skin cancer, AI shows great potential. However, there is a significant discrepancy between expectations and true relev...
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Sep 1, 2020
ADVANTAGES OF ARTIFICIAL INTELLIGENCE (AI): With responsible, safe and successful use of artificial intelligence (AI), possible advantages in the field of dermato-oncology include the following: (1) medical work can focus on skin cancer patients, (2)...
IMPORTANCE: The use of artificial intelligence (AI) is expanding throughout the field of medicine. In dermatology, researchers are evaluating the potential for direct-to-patient and clinician decision-support AI tools to classify skin lesions. Althou...
Journal of cancer research and therapeutics
Jan 1, 2020
CONTEXT: Skin cancer is a complex and life-threatening disease caused primarily by genetic instability and accumulation of multiple molecular alternations.
PURPOSE: Medical records contain a wealth of useful, informative data points valuable for clinical research. Most data points are stored in semistructured or unstructured legacy documents and require manual data abstraction into a structured format t...
OBJECTIVE: Prognosis of patients with metastatic melanoma has dramatically improved over recent years because of the advent of antibodies targeting programmed cell death protein-1 (PD1). However, the response rate is ~40% and baseline biomarkers for ...